{"doi":"10.1055/s-0036-1596948","title":"A-type proanthocyanidins selectively target acute myeloid leukemia cells in vitro and in vivo","abstract":null,"journal":"Planta Medica","year":2016,"id":621474,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1604843,"name":"H Zong","orcid":null,"position":1,"is_corresponding":false},{"id":1604844,"name":"LAL Martinez","orcid":null,"position":2,"is_corresponding":false},{"id":1604845,"name":"C Neto","orcid":null,"position":3,"is_corresponding":false},{"id":1604846,"name":"GJ Roboz","orcid":null,"position":4,"is_corresponding":false},{"id":1604847,"name":"S Rivella","orcid":null,"position":5,"is_corresponding":false},{"id":1604848,"name":"ML Guzman","orcid":null,"position":6,"is_corresponding":false},{"id":1604841,"name":"LM Bystrom","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"A-type proanthocyanidins selectively target acute myeloid leukemia cells in vitro and in vivo","abstract":"Acute myelogenous leukemia (AML) is often a fatal disease where after strong induction therapy most patients relapse and die [1, 2]. A-type proanthocyanidins (A-PACs) are a unique class of compounds found in cranberries (Vaccinium macrocarpon Ait.) that we have found to be effective against several leukemia cell lines and primary AML samples in vitro. An A-PAC fraction, isolated from the cranberry powder CystiCran®40 (Naturex; Avignon, France), was found to selectively ablate leukemia stem and progenitor cells, with minimal effects on normal hematopoetic stem cells. Furthermore, AML engraftment of cells treated ex vivo with 62.5 µg/ml A-PACs was decreased compared to controls (90.6%, n = 3, P < 0.001), whereas normal CD34+ cells retained engraftment capability in immunodeficient mice. Administration of A-PACs to AML-patient derived xenotransplants (PDX) significantly reduced tumor burden in mice. Specifically, mice treated with 50 mg/kg and 25 mg/kg of A-PACs exhibited a 56.8% (n = 5) and 58.4% (n = 5) reduction in tumor burden, respectively, compared to the mice treated with the vehicle control (P < 0.05). These effects were better or equal to those observed in mice treated with high-dose cytarabine, a standard care drug. Moreover, no toxic effects were observed in the mice. These results indicate that A-PACs not only target primary AML cells in vitro, but are also effective in vivo by potentially a novel mechanism that may also target stem cells. Further elucidation of this mechanism may uncover new vulnerabilities of AML.","is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"19910364","pmcid":null,"openalex_id":"https://openalex.org/W2563490026","authors":[],"funders":[],"total_grants":0,"fwci":0.0,"citation_percentile":0.06801608,"influential_citations":0,"citation_trend":[],"oa_status":"closed","license":null,"oa_locations":[{"url":"http://www.thieme-connect.de/products/ejournals/html/10.1055/s-0036-1596948","host_type":"publisher"},{"url":"https://doi.org/10.1055/s-0036-1596948","host_type":"journal"}],"fields_of_study":["Berry genetics and cultivation research"],"mesh_terms":[],"keywords":["In vivo","Leukemia","Myeloid leukemia","CD34","Stem cell","Cancer research","Pharmacology","Ex vivo","Progenitor cell","Cytarabine","Medicine","In vitro","Transplantation","Acute leukemia","Immunology","Biology","Internal medicine","Biochemistry","Cell biology"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-03T14:42:52.931304Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}